Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Recent approvals of apalutamide, enzalutamide, and darolutamide have significantly advanced nonmetastatic castration-resistant prostate cancer (nmCRPC) treatment.
• These second-generation androgen receptor inhibitors present complex choices for clinicians and patients.

Purpose of the Study:

• To discuss the efficacy and safety profiles of apalutamide, enzalutamide, and darolutamide.
• To emphasize the critical importance of safety considerations in treatment selection for nmCRPC.
• To propose a comprehensive approach to evaluating treatment safety, including potential adverse events and healthcare complications.

Main Methods:

• Review of current literature on the efficacy and safety of apalutamide, enzalutamide, and darolutamide.
• Analysis of safety considerations within the context of patient preferences, caregiver input, and clinical characteristics.
• Examination of the broader implications of treatment-emergent adverse events and drug-drug interactions.

Main Results:

• Second-generation androgen receptor inhibitors demonstrate significant efficacy in nmCRPC.
• Safety profiles vary among these agents, necessitating individualized assessment.
• Potential adverse events and drug-drug interactions require careful management.

Conclusions:

• Treatment selection for nmCRPC should prioritize a thorough evaluation of drug safety.
• A holistic approach considering patient-specific factors and the potential for cascading healthcare complications is essential.
• Informed decision-making regarding apalutamide, enzalutamide, and darolutamide hinges on balancing efficacy with comprehensive safety assessment.